Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System trimmed its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 9.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,784 shares of the medical research company's stock after selling 4,446 shares during the period. New York State Teachers Retirement System owned 0.08% of Charles River Laboratories International worth $6,139,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in CRL. Vanguard Group Inc. lifted its holdings in shares of Charles River Laboratories International by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after purchasing an additional 60,497 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Charles River Laboratories International by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock valued at $227,042,000 after purchasing an additional 14,787 shares during the period. Ariel Investments LLC boosted its stake in shares of Charles River Laboratories International by 18.9% during the 4th quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after acquiring an additional 169,640 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Charles River Laboratories International by 17.1% during the fourth quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock valued at $190,910,000 after purchasing an additional 151,159 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

NYSE CRL traded down $0.31 on Wednesday, hitting $158.08. 431,147 shares of the company's stock traded hands, compared to its average volume of 1,346,360. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The firm's 50-day moving average price is $142.30 and its two-hundred day moving average price is $152.12. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The firm has a market capitalization of $7.76 billion, a PE ratio of -243.20, a P/E/G ratio of 5.21 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. Charles River Laboratories International's quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.27 earnings per share. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Mizuho lowered their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Barclays upped their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a report on Thursday, May 8th. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their target price for the company from $150.00 to $200.00 in a report on Wednesday. Finally, TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $174.54.

Insider Activity

In related news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president directly owned 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).